deferoxamine has been researched along with Osteoporosis in 15 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 5.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39." | 3.83 | Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016) |
| "With regard to bone resorption and remodeling markers, the urinary excretion of pyridinium crosslinks was higher in patients with thalassemia for HP fraction (p < 0." | 1.33 | Chelation therapy and bone metabolism markers in thalassemia major. ( De Sanctis, V; Fornasari, PM; Fortini, M; Gamberini, MR; Marconi, S; Pratelli, L; Verri, E; Zolezzi, C, 2006) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 1.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, Z | 1 |
| Wang, H | 1 |
| Qi, G | 1 |
| Jiang, C | 1 |
| Chen, K | 1 |
| Yan, Z | 1 |
| Yi, L | 1 |
| Ju, Y | 1 |
| He, Y | 1 |
| Yin, X | 1 |
| Xu, Y | 3 |
| Weng, T | 1 |
| Wang, L | 2 |
| Jia, P | 2 |
| Shan, Y | 1 |
| Hao, Y | 1 |
| Wang, X | 1 |
| Jiang, Y | 1 |
| Yuan, Y | 2 |
| Du, Q | 1 |
| Zhang, H | 1 |
| Yang, F | 2 |
| Zhang, W | 1 |
| Sheng, M | 1 |
| Xu, F | 1 |
| Cao, Y | 1 |
| Xu, L | 1 |
| Yu, C | 1 |
| Zhang, P | 1 |
| Shen, G | 1 |
| Wang, J | 1 |
| Vrtačnik, P | 1 |
| Zupan, J | 1 |
| Mlakar, V | 1 |
| Kranjc, T | 1 |
| Marc, J | 1 |
| Kern, B | 1 |
| Ostanek, B | 1 |
| Poggi, M | 1 |
| Sorrentino, F | 1 |
| Pugliese, P | 1 |
| Smacchia, MP | 1 |
| Daniele, C | 1 |
| Equitani, F | 1 |
| Terlizzi, F | 1 |
| Guitarrini, MR | 1 |
| Monti, S | 1 |
| Maffei, L | 1 |
| Losardo, A | 1 |
| Pasin, M | 1 |
| Toscano, V | 1 |
| Chen, H | 1 |
| Kang, H | 1 |
| Qi, J | 1 |
| Zhao, P | 1 |
| Jiang, M | 1 |
| Guo, L | 1 |
| Zhou, Q | 1 |
| Qian, ND | 1 |
| Zhou, HB | 1 |
| Xu, YJ | 1 |
| Fan, Y | 1 |
| Deng, LF | 1 |
| Terpos, E | 1 |
| Voskaridou, E | 1 |
| Mokhtar, GM | 1 |
| Tantawy, AA | 1 |
| Adly, AA | 1 |
| Ismail, EA | 1 |
| Wu, KH | 1 |
| Chang, JS | 1 |
| Tsai, CH | 1 |
| Peng, CT | 1 |
| Vogiatzi, MG | 1 |
| Autio, KA | 1 |
| Mait, JE | 1 |
| Schneider, R | 1 |
| Lesser, M | 1 |
| Giardina, PJ | 1 |
| Pratelli, L | 1 |
| Verri, E | 1 |
| Fortini, M | 1 |
| Marconi, S | 1 |
| Zolezzi, C | 1 |
| Fornasari, PM | 1 |
| Gamberini, MR | 1 |
| De Sanctis, V | 1 |
| Wonke, B | 1 |
| Lasco, A | 1 |
| Morabito, N | 1 |
| Gaudio, A | 1 |
| Crisafulli, A | 1 |
| Meo, A | 1 |
| Denuzzo, G | 1 |
| Frisina, N | 1 |
| Chan, YL | 1 |
| Pang, LM | 1 |
| Chik, KW | 1 |
| Cheng, JC | 1 |
| Li, CK | 1 |
1 review available for deferoxamine and Osteoporosis
| Article | Year |
|---|---|
Bone disease in beta-thalassaemia major.
Topics: Anemia; beta-Thalassemia; Bone Diseases; Deferoxamine; Female; Humans; Male; Osteoporosis | 1998 |
14 other studies available for deferoxamine and Osteoporosis
| Article | Year |
|---|---|
Iron overload-induced ferroptosis of osteoblasts inhibits osteogenesis and promotes osteoporosis: An in vitro and in vivo study.
Topics: Animals; Deferoxamine; Dextrans; Ferroptosis; Glutathione; Iron; Iron Overload; Malondialdehyde; Mic | 2022 |
Intraperitoneal injection of Desferal® alleviated the age-related bone loss and senescence of bone marrow stromal cells in rats.
Topics: Animals; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Cellular Senescence; Deferoxamine | 2021 |
Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice.
Topics: Animals; Bone Density; Cancellous Bone; Cell Differentiation; Deferoxamine; Disease Models, Animal; | 2017 |
Iron Accumulation Leads to Bone Loss by Inducing Mesenchymal Stem Cell Apoptosis Through the Activation of Caspase3.
Topics: Animals; Apoptosis; Bone and Bones; Caspase 3; Cells, Cultured; Deferoxamine; Enzyme Activation; Iro | 2019 |
Epigenetic enzymes influenced by oxidative stress and hypoxia mimetic in osteoblasts are differentially expressed in patients with osteoporosis and osteoarthritis.
Topics: Acetylation; Bone and Bones; Cell Line; Chromatin; Deferoxamine; Epigenesis, Genetic; Epigenomics; E | 2018 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe | 2016 |
Deferoxamine released from poly(lactic-co-glycolic acid) promotes healing of osteoporotic bone defect via enhanced angiogenesis and osteogenesis.
Topics: Animals; Bone Regeneration; Cells, Cultured; Deferoxamine; Female; Femur; Human Umbilical Vein Endot | 2016 |
Treatment options for thalassemia patients with osteoporosis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Calcitonin; Clinical Trials as Topic; Defer | 2010 |
Clinicopathological and radiological study of Egyptian β-thalassemia intermedia and β-thalassemia major patients: relation to complications and response to therapy.
Topics: Absorptiometry, Photon; Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Chelation Therapy; | 2011 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D | 2004 |
Low bone mineral density in adolescents with beta-thalassemia.
Topics: Adolescent; Adult; Anthropometry; beta-Thalassemia; Blood Transfusion; Bone Density; Bone Diseases, | 2005 |
Chelation therapy and bone metabolism markers in thalassemia major.
Topics: Adult; Alkaline Phosphatase; beta-Thalassemia; Bone and Bones; Bone Resorption; Case-Control Studies | 2006 |
Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.
Topics: Adult; beta-Thalassemia; Biomarkers; Bone and Bones; Bone Density; Cross-Sectional Studies; Deferoxa | 2002 |
Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Bone and Bones; Bone Diseases, Developmental | 2002 |